drugset

drugset / Trial / NCT02402062

A Study to Assess the Safety and the Efficacy of the Combination of TH-302 and Sunitinib in Neuroendocrine Pancreatic Tumours

NCT02402062 ↗

Phase 2 Completed 17 enrolled Spanish Group for Research in Neuroendocrine Tumors Pfizer · collab Threshold Pharmaceuticals · collab

NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to determine the safety and the efficacy of the combination of the drugs TH-302 and sunitinib in metastatic neuroendocrine tumours.

Timeline

Start: 2015-05-11
Primary completion: 2018-05-31
Completion: 2020-01-10

Publications

Grande E, Rodriguez-Antona C, Lopez C, Alonso-Gordoa T, Benavent M, Capdevila J, Teule A, Custodio A, Sevilla I, Hernando J, Gajate P, Molina-Cerrillo J, Diez JJ, Santos M, Lanillos J, Garcia-Carbonero R. Sunitinib and Evofosfamide (TH-302) in Systemic Treatment-Naive Patients with Grade 1/2 Metastatic Pancreatic Neuroendocrine Tumors: The GETNE-1408 Trial. Oncologist. 2021 Nov;26(11):941-949. doi: 10.1002/onco.13885. Epub 2021 Jul 14.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Evofosfamide	Other / unclassified	340 mg/m2	Intravenous
Subject	Sunitinib	Small molecule	37.5 mg	Oral

Indications